Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past three months, 11 analysts have evaluated Jazz Pharmaceuticals (NASDAQ:JAZZ), with opinions ranging from bullish to bearish. The average 12-month price target is $163.73, down 4.25% from the previous $171.00. Several analysts have lowered their price targets, reflecting cautious sentiment.
August 01, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jazz Pharmaceuticals has received mixed analyst ratings over the past three months, with a notable decrease in the average 12-month price target from $171.00 to $163.73. Several analysts have lowered their price targets, indicating cautious sentiment.
The decrease in the average 12-month price target and the fact that several analysts have lowered their price targets suggest a cautious outlook on Jazz Pharmaceuticals. This could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100